ReviewOncoTargets and therapy2016

Next-generation EGFR/HER tyrosine kinase inhibitors for the treatment of patients with non-small-cell lung cancer harboring EGFR mutations: a review of the evidence.

Xiaochun Wang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.